@wombat777
This makes sense. Also as I understand, the purpose of a US-based phase 2/3 trial is for regulatory/FDA approval, as much as it is about collecting more data on efficacy.
I believe the concern over IND really has to do with shareholders' expectation of a transaction. The buyout objective was pushed from ~1 year to ~2/3 years as a result of cardio-protection discovery. Further delays could make some of the shareholders unhappy (regardless of increasing RAC's buyout value).
Ann: Race investor briefing invitation, page-17
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |